Abstract
Background:
Cardiac troponin I (cTnI), N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity C‐reactive protein (hsCRP) each predict adverse cardiac events in chronic heart failure (CHF). However, little is known about the utility of these novel biomarkers of CHF in combination.
Hypothesis:
We hypothesized that simultaneous assessment of the three biomarkers would enable clinicians to stratify risk more effectively among patients with advanced CHF.
Methods:
Measurements of the biomarkers were performed on 152 patients with symptomatic advanced CHF. Major adverse cardiac events during a median follow‐up period of 186 days were determined.
Results:
Univariate and multivariate analysis revealed that elevations of each biomarker were significant predictors of clinical outcome independently of clinical variables. When patients were categorized on the basis of the number of elevated biomarkers, patients with one, two and three elevated biomarkers respectively had a 2.7‐(p = 0.125), 8.6‐ (p < 0.0001) and 23.4‐(p < 0.0001) fold increase in the risk of adverse events.
Conclusions:
Simultaneous measurement of cTnI, hsCRP, and NT‐proBNP could provide complementary information and a simple multimarker strategy that categorizes the patients with advanced CHF based on the number of elevated biomarkers, allowing rapid risk stratification in these patients. Copyright © 2007 Wiley Periodicals, Inc.
Keywords: congestive heart failure, biomarkers, prognosis
Full Text
The Full Text of this article is available as a PDF (277.1 KB).
References
- 1. Stevenson LW, Couper G, Natterson B, Fonarow G, Hamilton MA, et al.: Target heart failure populations for newer therapies. Circulation 1995; 92((suppl II)): 174–181. [DOI] [PubMed] [Google Scholar]
- 2. Potluri S, Ventura HO, Mulumudi M, Mehra MR Cardiac troponin levels in heart failure. Cardiol Rev 2004; 12: 21–25. [DOI] [PubMed] [Google Scholar]
- 3. Rodeheffer RJ: Measuring plasma B‐type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 2004; 44: 740–749. [DOI] [PubMed] [Google Scholar]
- 4. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA: N‐terminal pro‐brain natriuretic peptide: a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735–1743. [DOI] [PubMed] [Google Scholar]
- 5. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, et al.: Independent prognostic value of elevated high‐sensitivity C‐reactive protein in chronic heart failure. Am Heart J 2004; 147: 931–938. [DOI] [PubMed] [Google Scholar]
- 6. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, et al.: Val‐HeFT Investigators: C‐reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112: 1428–1434. [DOI] [PubMed] [Google Scholar]
- 7. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, et al.: Multimarker approach to risk stratification in non‐ST elevation acute coronary syndrome: simultaneous assessment of troponin I, C‐reactive protein, and B‐type natriuretic peptide. Circulation 2002; 105: 1760–1763. [DOI] [PubMed] [Google Scholar]
- 8. Galvani M, Ferrini D, Ghezzi F, Ottani F: Cardiac markers and risk stratification: an integrated approach. Clin Chim Acta 2001; 311: 9–17. [DOI] [PubMed] [Google Scholar]
- 9. Mann DL: Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999; 100: 999–1008. [DOI] [PubMed] [Google Scholar]
- 10. Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, et al.: Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002; 89: 691–695. [DOI] [PubMed] [Google Scholar]
- 11. Ishii J, Cui W, Kitagawa F, Kuno T, Nakamura Y, et al.: Prognostic value of combination of cardiac troponin T and B‐type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 2003; 49: 2020–2026. [DOI] [PubMed] [Google Scholar]
- 12. Fonarow GC, Horwich TB: Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. Rev Cardiovasc Med 2003; 4((suppl 4)): S20–S28. [PubMed] [Google Scholar]